[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo Updates
January 12, 2000

Recent Therapeutic Advances in Dermatology

Author Affiliations

Author Affiliations: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Drs Lipper and Dover). Dr Arndt is a member of the JAMA Editorial Board and Editor of Archives of Dermatology.

 

Contempo Updates Section Editors: Thomas C. Jefferson, MD, Contributing Editor; Stephen J. Lurie, MD, PhD, Fishbein Fellow.

JAMA. 2000;283(2):175-177. doi:10.1001/jama.283.2.175

Recent advances in dermatologic therapy include the use of imiquimod beyond its original use as a treatment for anogenital condylomata acuminata. Another immunomodulating drug, tacrolimus, has been used topically to treat a variety of dermatoses. New concepts in the management of toxic epidermal necrolysis will also be discussed.

Imiquimod (Aldara, 3M Pharmaceuticals, St Paul, Minn), a novel immunomodulatory imidazoquinolin heterocyclic amine, has shown potent antiviral and antitumor action both experimentally and in recent clinical trials.16 In clinical practice, the drug was approved by the Food and Drug Administration for topical application as a treatment of anogenital condylomata acuminata, and can be easily applied to affected areas by the patient at home, with 5% imiquimod cream left on overnight (6-10 hours) and then washed off, used 3 days a week for 16 weeks or until all visible warts have disappeared.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×